References
- 1. Lirov R, Else T, Lerario AM, Hammer GD. Adrenal Tumors. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: principles & practice of oncology. 10h ed. Philadelphia: Wolters Kluwer Health / Lippincott Williams & Wilkins; 2015.
- 2. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the european network for the study of adrenal tumors. Eur J Endocrin. 2016;175(2):G1-34.
- 3. Kumari NS, Sireesha A, Jayashree K, Kumar OS. Spectrum of histomorphological patterns of adrenal tumors: A one year study at Gandhi Hospital, Hyderabad - A tertiary referral centre. IAIM, 2016; 3(7): 77-86.
- 4. Tang YZ, Bharwani N, Micco M, Akker S, Rockall AG, Sahdev A. The prevalence of incidentally detected adrenal enlargement on CT. Clin Radiol. 2014 Jan 31;69(1):e37-42.
- 5. Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol. 2008;190(5):1163-8.
- 6. Reginelli A, Di Grezia G, Izzo A, et al, 2014 Imaging of adrenal incidentaloma: our experience. Int J Surg 12: Suppl 1: 126-31.
- 7. Terzolo M, Stigliano A, Chiodini I, Loli P, Furlani L, Arnaldi G, et al. AME position statement on adrenal incidentaloma. Eur J Endocrin. 2011;164(6):851-70.
- 8. Patel RD, Vanikar AV, Suthar KS, Kanodia KV. Primary Adrenal Tumors-Five Years Single Centre Experience. J Pathol. 2012;2(04):107.
- 9. Morelli V, Palmieri S, Salcuni AS, et al. Bilateral and unilateral adrenal incidentalomas: biochemical and clinical characteristics. Eur J Endocrinol 2013;168:235–41.
- 10. Khanna S, Priya R, Bhartiya SK, Basu S, Shukla VK. Adrenal tumors: An experience of 10 years in a single surgical unit. Indian J Cancer. 2015;52(3):475.
- 11. Naidu V, Singh B. Adrenal lesions encountered in current medical practice − a review of their radiological imaging. S Afr J Rad. 2013;17:128–38. DOI:10.7196/SAJR.914.10.7196/sajr.914
- 12. Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, Fishman E & Kharlip J. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocrine Practice 2009;15:1–20.10.4158/EP.15.S1.1
- 13. Sundin A. Imaging of adrenal masses with emphasis on adrenocortical tumors. Theranostics. 2012;2:516-22.
- 14. Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 2007 Sep;14(3):587-99.1791409010.1677/ERC-07-0045
- 15. Maurea S, Mainenti PP, Ponsiglione A, Salvatore M. Advanced Adrenal Imaging: Comparison between Radionuclide and MR Techniques. J Adv Radiol Med Image. 2016;1(1):103.
- 16. Heinz-Peer G, Honigschnabl S, Schneider B, Niederle B, Kaserer K, Lechner G. Characterization of adrenal masses using MR imaging with histopathologic correlation. AJR Am J Roentgenol. 1999;173:15-22.
- 17. Blake MA, Cronin CG, Boland GW. Adrenal imaging. AJR Am J Roentgenol. 2010;194(6):1450-60
- 18. Boland GW, Lee M, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998;171(1):201-4.
- 19. Rubello D, Bui C, Casara D, Gross MD, Fig LM, Shapiro B. Functional scintigraphy of the adrenal gland. Eur J Endocrin. 2002;147(1):13-28.
- 20. Avram AM, Fig LM, Gross MD. Adrenal gland scintigraphy. Semin Nucl Med. 2006 Jul;36(3):212-27.10.1053/j.semnuclmed.2006.03.004
- 21. Blanchet EM, Martucci V, Pacak K. Pheochromocytoma and paraganglioma: current functional and future molecular imaging. Front Oncol. 2012;1:58.
- 22. McDermott S, McCarthy CJ, Blake MA. Images of pheochromocytoma in adrenal glands. Gland surg. 2015;4(4):350.
- 23. Maurea S, Mainenti PP, Ponsiglione A, Salvatore M. Advanced Adrenal Imaging: Comparison between Radionuclide and MR Techniques. J Adv Radiol Med Image. 2016;1(1):103.
- 24. Wiseman GA, Pacak K, O’Dorisio MS, Neumann DR, Waxman AD, Mankoff DA, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med. 2009;50(9):1448-54.
- 25. van Berkel A, Rao JU, Lenders JW, Pellegata NS, Kusters B, Piscaer I, Hermus AR, et al. Semiquantitative 123IMetaiodobenzylguanidine scintigraphy to distinguish pheochromocytoma and paraganglioma from physiologic adrenal uptake and its correlation with genotype-dependent expression of catecholamine transporters. J Nucl Med. 2015;56(6):839-46.
- 26. Ziegler CG, Brown JW, Schally AV, Erler A, Gebauer L, Treszl A, et al. Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues. Proc Natl Acad Sci USA. 2009;106(37):15879-84. doi: 10.1073/pnas.0907843106. Epub 2009 Aug 27.10.1073/pnas.0907843106.Epub2009Aug27
- 27. Pisarek H, St Thepieñ T, Kubiak R, Pawlikowski M. Somatostatin receptors in human adrenal gland tumors–immunohistochemical study. Folia Histochem Cytobiol. 2008;46(3):345-51. doi: 10.2478/v10042-008-0051-2.10.2478/v10042-008-0051-2
- 28. Prasad V, Fetscher S, Baum RP. Changing role of somatostatin receptor targeted drugs in NET: nuclear medicine’s view. J Pharm Pharm Sci. 2007;10(2):321s-7s
- 29. Maxwell JE, Howe JR. Imaging in neuroendocrine tumors: an update for the clinician. Int J Endocr Oncol. 2015;2:159–68.
- 30. Taïeb D, Timmers HJ, Hindié E, Guillet BA, Neumann HP, Walz MK, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2012;39(12):1977–95.
- 31. Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441–48.
- 32. Doknić M, Pekić S, Miljić D, Stojanović M, Soldatovic I, Petakov M. Etiology of hypopituitarism in adult patients: the experience of a single center database 1 in Serbian population. Int J Endocrinol. In press 2017. Available from: https://www.hindawi.com/journals/ije/aip/6969286/.10.1155/2017/6969286
- 33. Novakovic Paro J, Mitrovic M, Medis Stojanoska M, Bajkin I, Icin T, Tomic D, et al. Epidemiological study of adrenal mass in our clinical centre. 11th European Congress of Endocrinology, Istanbul, Turkey 2009, Endocrine abstracts, vol 20, P 38.
- 34. Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer. 2014;38(1):7-41. doi: 10.1016/j.currproblcancer.2014.01.001. Epub 2014 Jan 15.10.1016/j.currproblcancer.2014.01.001.Epub201415
- 35. Kapoor A, Morris T, Rebello R. Guidelines for the management of the incidentally discovered adrenal mass. Can Urol Assoc J 2011;5:241–247.
- 36. Northcutt BG, Raman SP, Long C, Oshmyansky AR, Siegelman SS, Fishman EK, et al. MDCT of adrenal masses: can dual-phase enhancement patterns be used to differentiate adenoma and pheochromocytoma?. Am J Roentgenol. 2013;201(4):834-9.
- 37. Schieda N, Alrashed A, Flood TA, Samji K, Shabana W, McInnes MD. Comparison of quantitative MRI and CT washout analysis for differentiation of adrenal pheochromocytoma from adrenal adenoma. Am J Roentgenol. 2016;206(6):1141-8.
- 38. Leung K, Stamm M, Raja A, Low G. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. Am J Roentgenol. 2013 Feb;200(2):370–378
- 39. Van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. [123I] metaiodobenzylguanidine and [111In] octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86(2):685-93.